SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 253.76 |
| Enterprise Value ($M) | 244.09 |
| Book Value ($M) | 125.70 |
| Book Value / Share | 2.14 |
| Price / Book | 2.02 |
| NCAV ($M) | 76.58 |
| NCAV / Share | 1.30 |
| Price / NCAV | 3.31 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.50 |
| Return on Assets (ROA) | -0.40 |
| Return on Equity (ROE) | -0.48 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.84 |
| Current Ratio | 4.84 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 124.60 |
| Assets | 173.73 |
| Liabilities | 48.02 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -80.42 |
| Net Income | -73.79 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -70.71 |
| Cash from Investing | -104.85 |
| Cash from Financing | 5.93 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Sullivan Lara | 8.89 | 31.64 | |
| 13G | Deep Track Capital, LP | 7.87 | ||
| 13G/A | Tang Capital Partners Lp | 0.00 | -100.00 | |
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
| 13G | Ridgeback Capital Investments L.P. | 9.80 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 186,929 | 678,335 | 27.56 | |
| 57,882 | 338,618 | 17.09 | |
| 231,804 | 818,440 | 28.32 | |
| 49,280 | 58,163 | 84.73 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PRLD – Prelude Therapeutics Incorporated | PRTA – Prothena Corporation plc |
| PTCT – PTC Therapeutics, Inc. | QDEL – QuidelOrtho Corporation |
| QNCX – Quince Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io